Human chorionic gonadotrophin contributes to the bioactivity of Pergonal
- 1 December 1992
- journal article
- Published by Wiley in Clinical Endocrinology
- Vol. 37 (6), 558-564
- https://doi.org/10.1111/j.1365-2265.1992.tb01488.x
Abstract
OBJECTIVE We examined batch variation in the LH‐like bioactive content of Pergonal and determined whether hCG contributes to this. DESIGN Random selection of three batches of Pergonal, consisting of three ampoules in each batch. MEASUREMENTS The LH content in each ampoule was determined by radioimmunoassay (R‐LH), immunoradio‐metric assay (l‐LH) and in vitro Leydig cell bioassay (B‐LH) using the urinary hMG International Standard 70/45. Human chorionic gonadotrophin was determined by immunoradiometric assay (I‐hCG) using the hCG IRP 75/537. The isohormone content of each batch was examined by chromatofocussing over the range pH 4.5– 7.0 and the fractions collected were assayed for LH and hCG content. The variability in potency between batches was assessed by single factor analysis of variance. RESULTS THE GONADOTROPHIN CONTENT OF EACH BATCH (IU/AMPOULE, MEAN ± SEM, N=3 AMPOULES) WAS R‐LH (40.9 ± 0.5, 40.8 ± 0.2, 39.3 ± 0 7, P P < 0.001), B‐LH (27.3 ± 0.3,12.0 ± 0.9, 19.3 ± 0.9, P < 0001) AND I‐HCG (16.4 ± 0.7, 11.7 ± 0.2, 10.5 ± 0.5, P < 0.001). THE CHROMATOFOCUSSING RECOVERIES BELOW PH 5.5 EXPRESSED AS A PERCENTAGE OF THE TOTAL AMOUNT OF ANALYTE ELUTED FROM THE COLUMN AND COLLATED FOR ALL THREE BATCHES OF PERGONAL WERE (MEAN %± SD, N= 3 BATCHES) R‐LH (58.4 ± 4.0), I‐LH (41.3 ± 7.5), B‐LH (81.4 ± 2.8) AND I‐HCG (87.8 ± 3.7). CONCLUSIONS There was significant batch variation in the I‐LH, B‐LH and I‐hCG (P < 0.001) but not the R‐LH (P> 0.15) content of Pergonal. More than 80% of the total B‐LH recovery chromatofocussed below pH 5.5 and corresponded to the region of highest I‐hCG (>87%) and lowest I‐LH (< 42%) recovery. This was highly suggestive of hCG contributing to the LH‐like bioactivity of Pergonal.Keywords
This publication has 24 references indexed in Scilit:
- Comparativein Vitroandin VivoStudies on the Biological Characteristics of Recombinant Human Follicle-Stimulating HormoneEndocrinology, 1991
- Hypersecretion of luteinising hormone, infertility, and miscarriageThe Lancet, 1990
- Editorial: Biological to Immunological Ratios: Reevaluation of a ConceptJournal of Clinical Endocrinology & Metabolism, 1990
- Gonadotrophin glycosylation and functionJournal of Endocrinology, 1990
- Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome.BMJ, 1988
- Characterization of recombinant DNA derived-human luteinizing hormone in vitro and in vivo. Efficacy in ovulation induction and corpus luteum supportJAMA, 1988
- OVULATION OF A SINGLE DOMINANT FOLLICLE DURING TREATMENT WITH LOW‐DOSE PULSATILE FOLLICLE STIMULATING HORMONE IN WOMEN WITH POLYCYSTIC OVARY SYNDROMEClinical Endocrinology, 1987
- 8 Oocyte maturation inhibitorClinics in Endocrinology and Metabolism, 1986
- Reduced in‐vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phaseBJOG: An International Journal of Obstetrics and Gynaecology, 1985
- Evidence for a gonadotropin from nonpregnant subjects that has physical, immunological, and biological similarities to human chorionic gonadotropin.Proceedings of the National Academy of Sciences, 1976